| Description | This product is a human neutralizing antibody binding spike 1 of SARS-CoV-2. It exhibits strong inhibition of ACE2-WT spike binding. It has high affinity with RBD and neutralization efficiency against SARS-CoV-2 WT variants. The mAb failed to efficiently cross-neutralize Omicron due to attenuated affinity. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 (WT and Delta) |
| Epitope | RBD residues T345, R346, D442, K444, V445, and Y451 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut; SPR |
| Application Notes | The affinity was tested by BLI using 20 μg/mL the mAb in kinetics buffer for 300 s. The IC₅₀ value and neutralizing capacity to SARS-CoV-2 WT was determined by neutralization assay. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
